Loading...
Loading...
RARE| Name | Value |
|---|---|
| Revenues | 127.4M |
| Cost of Revenue | 12.1M |
| Gross Profit | 115.3M |
| Operating Expense | 237.4M |
| Operating I/L | -122.0M |
| Other Income/Expense | -4.8M |
| Interest Income | 8.6M |
| Pretax | -126.9M |
| Income Tax Expense | -3.7M |
| Net Income/Loss | -123.2M |
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative products for the treatment of rare and ultra-rare genetic diseases globally. Its biologic products, including Crysvita, Mepsevii, Dojolvi, and Evkeeza, target various rare diseases. The company also has a robust pipeline of product candidates, such as DTX401, DTX301, UX143, GTX-102, UX701, and UX053, addressing different genetic disorders. Ultragenyx has established collaboration and license agreements with several prominent organizations and pharmaceutical companies. Through these products and partnerships, Ultragenyx generates revenue by providing therapeutic solutions for rare genetic diseases.
